Table of Contents
Chapter- 1: INTRODUCTION -- Complimentary 4
- STUDY OBJECTIVES 1
- REASONS FOR DOING THIS STUDY 1
- INTENDED AUDIENCE 2
- SCOPE OF THE STUDY 2
- METHODOLOGY 2
- INFORMATION SOURCES 2
- ABOUT THE AUTHOR 3
- RELATED BCC REPORTS 3
- BCC ONLINE SERVICES 4
- DISCLAIMER 4
Chapter-2: SUMMARY 2
- SUMMARY 5
- SUMMARY TABLE GLOBAL SALES FOR DRUG DELIVERY PRODUCTS, THROUGH 2014 ($
BILLIONS) 6
- SUMMARY FIGURE GLOBAL SALES FOR DRUG DELIVERY PRODUCTS, 2007-2014 ($
BILLIONS) 6
Chapter-3: OVERVIEW 18
- DEFINITIONS 7
- NEED FOR THE DOSAGE FORMS 7
- CLASSIFICATION OF DOSAGE FORMS ACCORDING TO PHYSICAL PROPERTIES 8
- GASEOUS DOSAGE FORMS 8
- TABLE 1 GASEOUS DOSAGE FORMS, ADVANTAGES AND DISADVANTAGES 9
- LIQUID DOSAGE FORMS 9
- TABLE 2 LIQUID DOSAGE FORMS, ADVANTAGES AND DISADVANTAGES 9
- SEMISOLID DOSAGE FORMS 10
- TABLE 3 SEMISOLID DOSAGE FORMS, ADVANTAGES AND DISADVANTAGES 10
- SOLID DOSAGE FORMS 10
- TABLE 4 SOLID DOSAGE FORMS, ADVANTAGES AND DISADVANTAGES 11
- CLASSIFICATION OF DRUG DELIVERY ACCORDING TO ROUTE OF ADMINISTRATION 11
- TOPICAL DRUG DELIVERY 12
- TABLE 5 TOPICAL DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES 12
- ORAL DRUG DELIVERY 13
- TABLE 6 ORAL DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES 13
- INJECTABLE OR PARENTERAL DRUG DELIVERY 13
- TABLE 7 INJECTABLE OR PARENTERAL DRUG DELIVERY, ADVANTAGES AND
DISADVANTAGES 14
- RECTAL DRUG DELIVERY 14
- TABLE 8 RECTAL DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES 15
- NASAL DRUG DELIVERY 15
- TABLE 9 NASAL DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES 15
- TABLE 9 (CONTINUED) 16
- VAGINAL DRUG DELIVERY 16
- TABLE 10 VAGINAL DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES 16
- OCULAR DRUG DELIVERY 17
- TABLE 11 OCULAR DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES 17
- PULMONARY DRUG DELIVERY 17
- TABLE 12 PULMONARY DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES 18
- CLASSIFICATION OF DRUG DELIVERY BASED ON TECHNOLOGY 18
- SUSTAINED-RELEASE DRUG DELIVERY 18
- TABLE 13 SUSTAINED-RELEASE DELIVERY, ADVANTAGES AND DISADVANTAGES 19
- DELAYED-RELEASE DRUG DELIVERY 19
- TABLE 14 DELAYED-RELEASE DELIVERY, ADVANTAGES AND DISADVANTAGES 19
- PRODRUGS 20
- TABLE 15 PRODRUGS, ADVANTAGES AND DISADVANTAGES 20
- IMPLANTS AND IUDS 20
- TABLE 16 IMPLANTS AND IUDS, ADVANTAGES AND DISADVANTAGES 21
- TARGETED DRUG DELIVERY 21
- Nanoparticles 21
- Liposomes 22
- TABLE 17 LIPOSOMES, ADVANTAGES AND DISADVANTAGES 22
- Polymers 22
- TABLE 18 POLYMERS, ADVANTAGES AND DISADVANTAGES 23
- Monoclonal Antibodies 23
- TABLE 19 MONOCLONAL ANTIBODIES, ADVANTAGES AND DISADVANTAGES 24
- PEGylation 24
- TABLE 20 PEGYLATION, ADVANTAGES AND DISADVANTAGES 24
Chapter-4: REGULATORY ISSUES 7
- TABLE 21 FDA-APPROVED DRUGS OF VARIOUS DOSAGE FORMS (2005 TO FEB 2009) 25
- TABLE 21 (CONTINUED) 26
- TABLE 21 (CONTINUED) 27
- TABLE 22 NUMBER OF NEW APPROVALS FOR DRUG DELIVERY PRODUCTS IN EACH YEAR,
2005- FEB. 2009 28
- FIGURE 1 NUMBER OF NEW APPROVALS FOR DRUG DELIVERY PRODUCTS IN EACH YEAR,
2005 TO FEB. 2009 28
- TABLE 23 APPROVED DRUGS OF VARIOUS DOSAGE FORMS, THROUGH OTHER AGENCIES
(2005 TO FEB 2009) 29
- TABLE 24 RECALLS/ SAFETY ALERTS FOR DRUG DELIVERY SYSTEMS (2005 TO FEB.
2009) 29
- TABLE 24 (CONTINUED) 30
- REGULATORY ISSUES (CONTINUED) 31
Chapter-5: CLASSIFICATION OF DRUG PRODUCTS BASED ON DRUG DELIVERY TYPE 14
- SUSTAINED-RELEASE ORAL DOSAGE FORMS 32
- TABLE 25 MAJOR SUPPLIERS AND MANUFACTURERS OF SUSTAINED-RELEASE ORAL
DOSAGE FORMS 32
- TABLE 25 (CONTINUED) 33
- SUSTAINED-RELEASE INJECTABLE DOSAGE FORMS 34
- TABLE 26 MAJOR SUPPLIERS AND MANUFACTURERS OF SUSTAINED-RELEASE INJECTABLE
DOSAGE FORMS 34
- SUSTAINED-RELEASE TOPICAL DOSAGE FORMS 35
- TABLE 27 MAJOR SUPPLIERS AND MANUFACTURERS OF SUSTAINED-RELEASE TOPICAL
DOSAGE FORMS 35
- PRODRUGS 35
- TABLE 28 MAJOR SUPPLIERS AND MANUFACTURERS OF PRODRUGS 35
- TABLE 28 (CONTINUED) 36
- IMPLANTS AND IUDS 36
- TABLE 29 MAJOR SUPPLIERS AND MANUFACTURERS OF IMPLANTS AND IUDS 36
- TRANSDERMAL DRUG DELIVERY SYSTEMS 36
- TABLE 30 MAJOR SUPPLIERS AND MANUFACTURERS OF TRANSDERMAL DRUG DELIVERY
SYSTEMS 36
- TABLE 30 (CONTINUED) 37
- LIPOSOMES 38
- TABLE 31 MAJOR SUPPLIERS AND MANUFACTURERS OF LIPOSOMES 38
- NANOPARTICLES 38
- TABLE 32 MAJOR SUPPLIERS AND MANUFACTURERS OF NANOPARTICLES 38
- POLYMERS 39
- TABLE 33 MAJOR SUPPLIERS AND MANUFACTURERS OF POLYMERS 39
- MONOCLONAL ANTIBODIES 40
- TABLE 34 MAJOR SUPPLIERS AND MANUFACTURERS OF MONOCLONAL ANTIBODIES 40
- PEGYNOLOGY 41
- TABLE 35 MAJOR SUPPLIERS AND MANUFACTURERS OF PEGNOLOGY 41
- BUCCAL DRUG DELIVERY SYSTEMS 41
- TABLE 36 MAJOR SUPPLIERS AND MANUFACTURERS OF BUCCAL DRUG DELIVERY SYSTEMS
41
- RECTAL DRUG DELIVERY SYSTEMS 42
- TABLE 37 MAJOR SUPPLIERS AND MANUFACTURERS OF RECTAL DRUG DELIVERY SYSTEMS
42
- VAGINAL DRUG DELIVERY SYSTEMS 42
- TABLE 38 MAJOR SUPPLIERS AND MANUFACTURERS OF VAGINAL DRUG DELIVERY
SYSTEMS 42
- TABLE 7 (CONTINUED) 43
- OCULAR DRUG DELIVERY SYSTEMS 43
- TABLE 39 MAJOR SUPPLIERS AND MANUFACTURERS OF OCULAR DRUG DELIVERY SYSTEMS
43
- TABLE 39 (CONTINUED) 44
- INHALATION SYSTEMS 44
- TABLE 40 MAJOR SUPPLIERS AND MANUFACTURERS OF INHALTION SYSTEMS 44
- TABLE 40 (CONTINUED) 45
Chapter-6: INDUSTRY STRUCTURE 18
- SUSTAINED-RELEASE DOSAGE FORMS 46
- SUSTAINED-RELEASE ORAL DOSAGE FORM 46
- TABLE 41 SHARES OF MANUFACTURERS/SUPPLIERS FOR SUSTAINED-RELEASE ORAL
DOSAGE FORMS, 2008 (%) 46
- FIGURE 2 SHARES OF MANUFACTURERS/SUPPLIERS OF SUSTAINED-RELEASE ORAL
DOSAGE FORMS, 2008 (%) 47
- SUSTAINED-RELEASE INJECTABLE DOSAGE FORM 48
- TABLE 42 SHARES OF MANUFACTURERS/SUPPLIERS FOR SUSTAINED-RELEASE
INJECTABLE DOSAGE FORMS, 2008 (%) 48
- FIGURE 3 SHARES OF MANUFACTURERS/SUPPLIERS OF SUSTAINED-RELEASE INJECTABLE
DOSAGE FORMS, 2008 (%) 48
- SUSTAINED-RELEASE TOPICAL DOSAGE FORM 49
- TABLE 43 SHARES OF MANUFACTURERS/SUPPLIERS FOR SUSTAINED-RELEASE TOPICAL
DOSAGE FORMS, 2008 (%) 49
- FIGURE 4 SHARES OF MANUFACTURERS/SUPPLIERS OF SUSTAINED-RELEASE TOPICAL
DOSAGE FORMS, 2008 (%) 49
- PRODRUGS 50
- TABLE 44 SHARES OF MANUFACTURERS/SUPPLIERS FOR PRODRUGS, 2008 (%) 50
- FIGURE 5 SHARES OF MANUFACTURERS/SUPPLIERS OF PRODRUGS, 2008 (%) 50
- IMPLANTS AND IUDS 51
- TABLE 45 SHARES OF MANUFACTURERS FOR IMPLANTS AND IUDS, 2008 (%) 51
- FIGURE 6 SHARES OF MANUFACTURERS OF IMPLANTS AND IUDS, 2008 (%) 51
- TRANSDERMAL DRUG DELIVERY SYSTEMS 52
- TABLE 46 SHARES OF MANUFACTURERS/SUPPLIERS FOR TRANSDERMAL DRUG DELIVERY
SYSTEMS, 2008 (%) 52
- FIGURE 7 SHARES OF MANUFACTURERS/SUPPLIERS OF TRANSDERMAL DRUG DELIVERY
SYSTEMS, 2008 (%) 52
- TARGETED DRUG DELIVERY SYSTEMS 53
- LIPOSOMES 53
- TABLE 47 SHARES OF MANUFACTURERS/SUPPLIERS FOR LIPOSOMES, 2008 (%) 53
- FIGURE 8 SHARES OF MANUFACTURERS/SUPPLIERS OF LIPOSOMES, 2008 (%) 53
- NANOPARTICLES 54
- TABLE 48 SHARES OF MANUFACTURERS/SUPPLIERS FOR NANOPARTICLES, 2008 (%) 54
- FIGURE 9 SHARES OF MANUFACTURERS/SUPPLIERS OF NANOPARTICLES, 2008 (%) 54
- POLYMERS 55
- TABLE 49 SHARES OF MANUFACTURERS/SUPPLIERS FOR POLYMERS, 2008 (%) 55
- FIGURE 10 SHARES OF MANUFACTURERS/SUPPLIERS OF POLYMERS, 2008 (%) 55
- MONOCLONAL ANTIBODIES 56
- TABLE 50 SHARES OF MANUFACTURERS/SUPPLIERS FOR MONOCLONAL ANTIBODIES, 2008
(%) 56
- FIGURE 11 SHARES OF MANUFACTURERS/SUPPLIERS OF MONOCLONAL ANTIBODIES, 2008
(%) 56
- PEGNOLOGY 57
- TABLE 51 SHARES OF MANUFACTURERS/SUPPLIERS FOR PEGNOLOGY, 2008 (%) 57
- FIGURE 12 SHARES OF MANUFACTURERS/SUPPLIERS OF PEGNOLOGY, 2008 (%) 57
- TRANSMUCOSAL DRUG DELIVERY SYSTEMS 58
- BUCCAL DRUG DELIVERY SYSTEMS 58
- TABLE 52 SHARES OF MANUFACTURERS/SUPPLIERS FOR BUCCAL DRUG DELIVERY
SYSTEMS, 2008 (%) 58
- FIGURE 13 SHARES OF MANUFACTURERS/ SUPPLIERS OF BUCCAL DRUG DELIVERY
SYSTEMS, 2008 (%) 58
- RECTAL DRUG DELIVERY SYSTEMS 59
- TABLE 53 SHARES OF MANUFACTURERS/SUPPLIERS FOR RECTAL DRUG DELIVERY
SYSTEMS, 2008 (%) 59
- FIGURE 14 SHARES OF MANUFACTURERS/ SUPPLIERS OF RECTAL DRUG DELIVERY
SYSTEMS, 2008 (%) 59
- VAGINAL DRUG DELIVERY SYSTEMS 60
- TABLE 54 SHARES OF MANUFACTURERS/SUPPLIERS FOR VAGINAL DRUG DELIVERY
SYSTEMS, 2008 (%) 60
- FIGURE 15 SHARES OF MANUFACTURERS/ SUPPLIERS OF VAGINAL DRUG DELIVERY
SYSTEMS, 2008 (%) 60
- OCULAR DRUG DELIVERY SYSTEMS 61
- TABLE 55 SHARES OF MANUFACTURERS/SUPPLIERS FOR OCULAR DRUG DELIVERY
SYSTEMS, 2008 (%) 61
- FIGURE 16 SHARES OF MANUFACTURERS/SUPPLIERS OF OCULAR DRUG DELIVERY
SYSTEMS, 2008 (%) 61
- INHALATION SYSTEMS 62
- TABLE 56 SHARES OF MANUFACTURERS/SUPPLIERS OF INHALATION SYSTEMS, 2008 (%)
62
- FIGURE 17 SHARES OF MANUFACTURERS/SUPPLIERS OF INHALATION SYSTEMS, 2008
(%) 62
- Inhalation Systems (Continued) 63
Chapter-7: DEMAND AND USE 4
- TABLE 59 GLOBAL SALES OF DRUG DELIVERY PRODUCTS, THROUGH 2014 ($ BILLIONS)
68
- FIGURE 18 GLOBAL SALES OF DRUG DELIVERY SYSTEMS, 2007-2014 ($ BILLIONS) 69
- TABLE 60 MARKET SHARE OF DRUG DELIVERY PRODUCTS, 2008 (%) 69
- FIGURE 19 MARKET SHARE OF DRUG DELIVERY SYSTEM, 2008 (%) 70
- SUSTAINED-RELEASE ORAL DOSAGE FORMS 70
- MARKET SIZE 71
- TABLE 61 GLOBAL SALES OF SUSTAINED-RELEASE ORAL DOSAGE FORMS, THROUGH 2014
($ MILLIONS) 71
- FIGURE 20 TOTAL GLOBAL SALES OF SUSTAINED-RELEASE ORAL DOSAGE FORMS,
2007-2014 ($ MILLIONS) 72
- MARKET OVERVIEW 72
- SUSTAINED-RELEASE INJECTABLE DOSGAE FORM 73
- MARKET SIZE 74
- TABLE 62 GLOBAL SALES OF SUSTAINED-RELEASE INJECTABLE DOSAGE FORMS,
THROUGH 2014 ($ MILLIONS) 74
- FIGURE 21 TOTAL GLOBAL SALES OF SUSTAINED-RELEASE INJECTABLE DOSAGE FORMS,
2007-2014 ($ MILLIONS) 75
- MARKET OVERVIEW 75
- SUSTAINED-RELEASE TOPICAL DOSAGE FORMS 76
- MARKET SIZE 76
- TABLE 63 GLOBAL SALES OF SUSTAINED-RELEASE TOPICAL DOSAGE FORMS, THROUGH
2014 ($ MILLIONS) 76
- FIGURE 22 TOTAL GLOBAL SALES OF SUSTAINED-RELEASE TOPICAL DOSAGE FORMS,
2007-2014 ($ MILLIONS) 77
- MARKET OVERVIEW 77
- PRODRUGS 78
- MARKET SIZE 78
- TABLE 64 TOTAL GLOBAL SALES OF PRODRUGS, THROUGH 2014 ($ MILLIONS) 79
- FIGURE 23 GLOBAL SALES OF PRODRUGS, 2007-2014 ($ MILLIONS) 79
- MARKET OVERVIEW 79
- IMPLANTS AND IUDS 80
- MARKET SIZE 80
- TABLE 65 GLOBAL SALES OF IMPLANTS AND IUDS, THROUGH 2014 ($ MILLIONS) 81
- FIGURE 24 TOTAL GLOBAL SALES OF IMPLANTS AND IUDS, 2007-2014 ($ MILLIONS)
81
- MARKET OVERVIEW 81
- TRANSDERMAL DRUG DELIVERY 82
- MARKET SIZE 82
- TABLE 66 GLOBAL SALES OF TRANSDERMAL DRUG DELIVERY SYSTEMS, THROUGH 2014
($ MILLIONS) 83
- FIGURE 25 TOTAL GLOBAL SALES OF TRANSDERMAL DRUG DELIVERY SYSTEMS,
2007-2014 ($ MILLIONS) 83
- MARKET OVERVIEW 83
- LIPOSOMES DRUG DELIVERY 84
- MARKET SIZE 84
- TABLE 67 GLOBAL SALES OF LIPOSOMES, THROUGH 2014 ($ MILLIONS) 85
- FIGURE 26 TOTAL GLOBAL SALES OF LIPOSOMES, 2007-2014 ($ MILLIONS) 85
- MARKET OVERVIEW 85
- NANOPARTICLES 86
- MARKET SIZE 86
- TABLE 68 GLOBAL SALES OF NANOPARTICLES, THROUGH 2014 ($ MILLIONS) 87
- FIGURE 27 GLOBAL SALES OF NANOPARTICLES, 2007-2014 ($ MILLIONS) 87
- MARKET OVERVIEW 87
- POLYMERS 88
- MARKET SIZE 88
- TABLE 69 GLOBAL SALES OF POLYMERS, THROUGH 2014 ($ MILLIONS) 88
- FIGURE 28 GLOBAL SALES OF POLYMERS, 2007-2014 ($ MILLIONS) 89
- MARKET OVERVIEW 89
- PEGYLATED DRUG DELIVERY 90
- MARKET SIZE 90
- TABLE 70 GLOBAL SALES OF PEGYLATED DRUG DELIVERY, THROUGH 2014 ($
MILLIONS) 90
- FIGURE 29 TOTAL GLOBAL SALES OF PEGYLATED DRUG DELIVERY, 2007-2014 ($
MILLIONS) 91
- MARKET OVERVIEW 91
- MONOCLONAL ANTIBODIES 92
- MARKET SIZE 92
- TABLE 71 GLOBAL SALES OF MONOCLONAL ANTIBODIES, THROUGH 2014 ($ MILLIONS)
92
- FIGURE 30 TOTAL GLOBAL SALES OF MONOCLONAL ANTIBODIES, 2007-2014 ($
MILLIONS) 93
- MARKET OVERVIEW 93
- BUCCAL DRUG DELIVERY 94
- MARKET SIZE 94
- TABLE 72 GLOBAL SALES OF BUCCAL DRUG DELIVERY, THOUGH 2014 ($ MILLIONS) 94
- FIGURE 31 TOTAL GLOBAL SALES OF BUCCAL DRUG DELIVERY, 2007-2014 ($
MILLIONS) 95
- MARKET OVERVIEW 95
- RECTAL DRUG DELIVERY 96
- MARKET SIZE 96
- TABLE 73 GLOBAL SALES OF RECTAL DRUG DELIVERY, THROUGH 2014 ($ MILLIONS) 96
- FIGURE 32 TOTAL GLOBAL SALES OF RECTAL DRUG DELIVERY, 2007-2014 ($
MILLIONS) 97
- MARKET OVERVIEW 97
- OCULAR DRUG DELIVERY 97
- MARKET SIZE 98
- TABLE 74 GLOBAL SALES OF OCULAR DRUG DELIVERY, THROUGH 2014 ($ MILLIONS) 98
- FIGURE 33 TOTAL GLOBAL SALES OF OCULAR DRUG DELIVERY, 2007-2014 ($
MILLIONS) 98
- MARKET OVERVIEW 99
- VAGINAL DRUG DELIVERY 99
- MARKET SIZE 99
- TABLE 75 GLOBAL SALES OF VAGINAL DRUG DELIVERY, THROUGH 2014 ($ MILLIONS)
100
- FIGURE 34 TOTAL GLOBAL SALES OF VAGINAL DRUG DELIVERY, 2007-2014 ($
MILLIONS) 100
- MARKET OVERVIEW 100
- INHALATION DRUG DELIVERY 101
- MARKET SIZE 101
- TABLE 76 GLOBAL SALES OF INHALATION DRUG DELIVERY, THROUGH 2014 ($
MILLIONS) 101
- FIGURE 35 TOTAL GLOBAL SALES OF INHALATION DRUG DELIVERY, 2007-2014 ($
MILLIONS) 102
- MARKET OVERVIEW 102
- Market Overview (Continued) 103
Chapter-8: MARKET ANALYSIS 36
Chapter-9: NEW DEVELOPMENTS 13
- TABLE 77 DEVELOPMENTS IN SUSTAINED-RELEASE ORAL DOSAGE FORMS 104
- TABLE 77 (CONTINUED) 105
- TABLE 78 DEVELOPMENTS IN SUSTAINED-RELEASE INJECTABLE DOSAGE FORMS 105
- TABLE 78 (CONTINUED) 106
- TABLE 79 DEVELOPMENTS IN SUSTAINED-RELEASE TOPICAL DOSAGE FORMS 106
- TABLE 80 DEVELOPMENTS IN PRODRUGS 106
- TABLE 80 (CONTINUED) 107
- TABLE 81 DEVELOPMENTS IN IMPLANTS AND IUDS 107
- TABLE 81 (CONTINUED) 108
- TABLE 82 DEVELOPMENTS IN TRANSDERMAL DRUG DELIVERY SYSTEMS 108
- TABLE 82 (CONTINUED) 109
- TABLE 83 DEVELOPMENTS IN LIPOSOMAL DELIVERY 109
- TABLE 83 (CONTINUED) 110
- TABLE 84 DEVELOPMENTS IN PEGYLATED DRUG DELIVERY 110
- TABLE 84 (CONTINUED) 111
- TABLE 85 DEVELOPMENTS IN NANOPARTICLE DRUG DELIVERY 112
- TABLE 86 DEVELOPMENTS IN MONOCLONAL ANTIBODIES 112
- TABLE 86 (CONTINUED) 113
- TABLE 87 DEVELOPMENTS IN BUCCAL DRUG DELIVERY 114
- TABLE 88 DEVELOPMENTS IN VAGINAL DRUG DELIVERY 114
- TABLE 89 DEVELOPMENTS IN RECTAL DRUG DELIVERY 115
- TABLE 90 DEVELOPMENTS IN INHALATION DRUG DELIVERY 115
- TABLE 90 (CONTINUED) 116
Chapter-10: MARKET BY THERAPEUTIC AREAS 19
- MARKET SIZE 117
- TABLE 91 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN EACH THERAPEUTIC AREA,
THROUGH 2014 ($ BILLIONS) 117
- TABLE 91 (CONTINUED) 118
- FIGURE 36 GLOBAL SALES OF DRUGS TO TREAT LIVER DISEASES, 2007-014 ($
BILLIONS) 118
- MARKET SHARE 119
- TABLE 92 SHARE OF DRUG DELIVERY SYSTEMS IN THERAPEUTIC AREAS, 2008 (%) 119
- FIGURE 37 SHARE OF DRUG DELIVERY SYSTEMS IN THERAPEUTIC AREAS, 2008 (%) 119
- CARDIOVASCULAR DISEASES 120
- MARKET SIZE 120
- TABLE 93 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN CARDIOVASCULAR DISEASES,
THROUGH 2004 ($ BILLIONS) 120
- FIGURE 38 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN CARDIOVASCULAR
DISEASES, 2007-2014 ($ BILLIONS) 121
- ONCOLOGY 121
- MARKET SIZE 121
- TABLE 94 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN ONCOLOGY, THROUGH 2014
($ BILLIONS) 122
- FIGURE 39 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN ONCOLOGY, 2007-2014 ($
BILLIONS) 122
- GASTROINTESTINAL 122
- MARKET SIZE 122
- TABLE 95 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN GASTROINTESTINAL
DISORDERS, THROUGH 2014 ($ BILLIONS) 123
- FIGURE 40 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN GASTROINTESTINAL
DISORDERS, 2007-2014 ($ BILLIONS) 123
- UROLOGY 123
- MARKET SIZE 124
- TABLE 96 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN UROLOGY, THROUGH 2014 ($
BILLIONS) 124
- FIGURE 41 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN UROLOGY, 2007-2014 ($
BILLIONS) 124
- DIABETES 125
- MARKET SIZE 125
- TABLE 97 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN DIABETIC MARKET, THROUGH
2014 ($ BILLIONS) 125
- FIGURE 42 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN DIABETIC MARKET,
2007-2014 ($ BILLIONS) 126
- CENTRAL NERVOUS SYSTEM DISORDER 126
- MARKET SIZE 126
- TABLE 98 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN CENTERAL NERVOUS SYSTEM
MARKET, THROUGH 2014 ($ BILLIONS) 127
- FIGURE 42 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN CENTRAL NERVOUS SYSTEM
MARKET, 2007-2014 ($ BILLIONS) 127
- RESPIRATORY DRUG DELIVERY SYSTEMS 127
- MARKET SIZE 128
- TABLE 99 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN RESPIRATORY DISEASES,
THROUGH 2014 ($ BILLIONS) 128
- FIGURE 44 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN RISPIRATORY DISEASES,
2007-2014 ($ BILLIONS) 128
- INFLAMMATORY DISEASES AND ALLERGY 128
- MARKET SIZE 129
- TABLE 100 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN INFLAMMATORY AND
ALLERGY, 2007-2014 ($ BILLIONS) 129
- FIGURE 45 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN INFLAMMATORY AND
ALLERGY DISEASES, 2007-2014 ($ BILLIONS) 129
- OPHTHALMOLOGY 130
- MARKET SIZE 130
- TABLE 101 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY, THROUGH
2014 ($ BILLIONS) 130
- FIGURE 46 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY,
2007-2014 ($ BILLIONS) 131
- VIRAL AND BACTERIAL DISEASES 131
- MARKET SIZE 131
- TABLE 102 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN VIRAL AND BACTERIAL
DISEASES, THROUGH 2014 ($ BILLIONS) 132
- FIGURE 47 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN VIRAL AND BACTERIAL
DISEASES, 2007-2014 ($ BILLIONS) 132
- HORMONE REPLACEMENT THERAPY (HRT) AND GYNECOLOGY 132
- MARKET SIZE 133
- TABLE 103 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN HORMONE REPLACEMENT
THERAPY AND GYNECOLOGY, THROUGH 2014 ($ BILLIONS) 133
- FIGURE 48 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN HORMONE REPLACEMENT
THERAPY AND GYNECOLOGY, 2007-2014 ($ BILLIONS) 133
- OTHERS 134
- MARKET SIZE 134
- TABLE 104 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN OTHER THERAPEUTIC AREAS
AND TECHNOLOGIES, THROUGH 2014 ($ BILLIONS) 134
- FIGURE 49 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN OTHER THERAPEUTIC AREAS
AND TECHNOLOGIES, 2007-2014 ($ BILLIONS) 135
Chapter-11: PATENT ANALYSIS 11
- PATENTS BY YEAR 136
- TABLE 105 TOTAL NUMBER OF PATENTS IN EACH YEAR, 2005-2009 137
- FIGURE 50 NUMBER OF PATENTS, 2005-2009 137
- PATENTS BY TYPE 137
- TABLE 106 NUMBER OF PATENTS BY TYPE, 2005-2009 138
- FIGURE 51 NUMBER OF PATENTS BY TYPE, 2005-2009 138
- FIGURE 52 TOTAL NUMBER OF PATENTS, SHARE BY TYPE, 2005-2009 (%) 139
- PATENTS BY COUNTRY 139
- TABLE 107 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2009 140
- FIGURE 53 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2009 141
- PATENTS BY COMPANY 141
- TABLE 108 NUMBER OF PATENTS BY COMPANY, 2005-2009 142
- TABLE 108 (CONTINUED) 143
- TABLE 108 (CONTINUED) 144
- FIGURE 54 NUMBER OF PATENTS BY COMPANY, 2005-2009 145
- PATENTS BY ASSIGNEE 145
- TABLE 109 NUMBER OF PATENTS BY ASSIGNEE, 2005-2009 145
- FIGURE 55 NUMBER OF PATENTS BY ASSIGNEE, 2005-2009 146
Chapter-12: COMPANY PROFILES 30
- ABBOTT LABORATORIES 147
- ABRAXIS BIOSCIENCE, INC. 147
- AKELA PHARMA 148
- AKORN, INC. 148
- ALCON, INC. 149
- ALEXION PHARMACEUTICALS 149
- ALKERMES, INC. 150
- ALLERGAN 150
- ALPHARX 151
- AMGEN 151
- ANTIGENICS 151
- A P PHARMA 152
- ASTELLAS PHARMA 152
- ASTRAZENECA 153
- ATON PHARMA 153
- BARR PHARMACEUTICALS, INC. 153
- BAXTER 154
- BAYER HEALTHCARE 154
- BIOGEN IDEC 155
- BIOSANTE PHARMACEUTICALS, INC. 155
- BIOVAIL 155
- BOEHRINGER INGELHEIM 156
- BRISTOL MYERS SQUIBB 156
- CENTOCOR 157
- CEPHALON INC. 157
- COLUMBIA LABS 157
- DIATOS SA 158
- EISAI CO. 158
- ELAN 159
- ENZON 159
- EURAND N.V. 159
- GENENTECH 160
- GENEREX BIOTECH 160
- GENZYME 161
- GILEAD SCIENCES, INC. 161
- GLAXOSMITHKLINE PLC 161
- IMCLONE SYSTEMS 162
- JOHNSON AND JOHNSON 162
- KING PHARMACEUTICALS 163
- K.V. PHARMACEUTICAL CO. 164
- LAVIPHARM CORPORATION 164
- 3M COMPANY 165
- MERCK & CO. 165
- MYLAN LABORATORIES, INC. 166
- NEKTAR THERAPEUTICS 166
- NOVEN PHARMACEUTICALS, INC. 167
- NOVARTIS AG 168
- NOVAVAX, INC. 168
- NYCOMED US, INC. 169
- OSI PHARMACEUTICALS, INC. 169
- PAR PHARMACEUTICAL COMPANIES, INC. 170
- PDL BIOPHARMA, INC. 170
- PFIZER INC. 170
- QLT, INC. 171
- ROCHE 171
- SANOFI-AVENTIS 172
- SCHERING-PLOUGH 172
- TEVA PHARMACEUTICAL INDUSTRIES, LTD. 173
- WATSON PHARMACEUTICALS, INC. 173
- WYETH, INC. 174
APPENDIX: ABBREVIATIONS 175
- ABBREVIATIONS 175
- APPENDIX (CONTINUED) 176
|
Related Report
|
View Cart
